Diabetic GI complications as gastric and colonic motility disturbances occur commonly in DM if it is of long duration and/or treated inappropriately. Recently, the importance of Kv7 (KCNQ) channels in controlling and regulating muscle tone and contraction in different tissues including the GI tract is highlighted by different studies. So, the aim of the present work is to study the effect of K V 7 channel modulators, Retigabine (K V 7 opener) and XE-991 (K V 7 blocker), on motility of both fundal and corpal gastric segments in rate model of type I DM. Methods: 24 Male Sprague Dawley rats were divided into 2 main groups: (I) control and (II) diabetic group (n=12) Each group was subdivided into 2 subgroups according to the used segment whether fundus or corpus. Each segment group was treated with retigabine (K V 7 opener) and XE-991 (K V 7 blocker) on basal and cholinergic stimulated motility. The motility was recorded in-vitro using the Power Lab data acquisition system. Results: Diabetic stomach significantly showed higher basal amplitude and higher basal fundal frequency of contractions when compared with the control group. Diabetic gastric response to A.ch is significantly higher as compared to control group.
INTRODUCTION
Diabetes Mellitus (DM) is a very common disease. Usually, it is associated with gastrointestinal (GI) manifestations which interfere with the daily life of the patient causing discomfort and disability. Diabetes affects nearly every part in the GIT from the esophagus to the rectum but the definite mechanism still unclear. The GI symptoms include heart burn, nausea, vomiting, abdominal pain, constipation and diarrhea (1; 2). Recently, not only autonomic neuropathy is the cause but enteric nervous system, gut microbiota and direct effect on GIT smooth muscles are also involved in the pathophysiology of the GI symptoms in diabetes (3). Recently, the importance of K v 7 (KCNQ) channels in controlling and regulating muscle tone and contraction in different tissues in the body including stomach and colon is highlighted by different studies.
So, as a further step in studying the possible mechanism that might participate in occurrence or controlling diabetic GI changes, the present work aimed to investigate whether the modulation of K v 7 channels by their agonist and blocker could affect the gastric smooth muscle motility changes in diabetic rats.
Experimental plan:
24 adult male Sprague Dawley rats weighing 200-250 grams were included in this study. The study was approved by the research ethics committee, faculty of medicine, Mansoura University, Egypt.
Chemicals:
 Acetylcholine Chloride, (C 7 H 16 CINO 2 ), freshly prepared by dissolving 1.09 milligrams in 2 milliliters distilled water,  Streptozotocin, freshly prepared by dissolving in cold Na citrate buffer (PH= 4.2).
 Retigabine, it is K V 7 channel opener. freshly prepared by dissolving 1.092 milligrams in dimethyl sulfoxide in a concentration of 0.025% then diluted with distilled water up to 3 milliliters (8).
 XE-991, it is K V 7 channel blocker. freshly prepared by dissolving 1.13 milligrams in dimethyl sulfoxide in a concentration of 0.025% then diluted with distilled water up to 1 milliliter (8).
All chemicals were in a powder form that purchased from Sigma Aldrich, Egypt.
Experimental groups:
Twenty four rats were divided into two main groups: (n=12 per group) I) control group. II) diabetic group.
Each group was subdivided into 2 subgroups based on the examined segment (gastric fundus and gastric corpus) , (n=6 per group):
The study consists of the following experiments on rat stomach in control (I) and diabetic (II)
groups:
A. 
Tissue fixation and basal recording:
The selected gastric specimens were fixed 
Statistical analysis
The 
N.B:
Interval of confidence equals 95% and significant P value < 0.05.
Results
The results were gathered from the recorded .001 -NS NS values expressed as mean ± standard deviation, n= number of specimens, NS= non-significant, P1=probability of significance compared to the basal, P2= probability of significance compared to A.ch, P3= probability of significance between control and diabetic groups, significant at < 0.05. -NS  NS  -NS  NS  -NS  NS  -NS  NS  ------NS  NS  NS  -NS  NS  values expressed as mean ± standard deviation, n= number of specimens, NS= non-significant, P1=probability of significance compared to the basal, P2= probability of significance compared to A.ch, P3= probability of significance between control and diabetic groups, significant at < 0.05. The response to A.ch is significantly higher in diabetic gastric strips than the control group (Table: 1 (Table: 1,2; Chart 9). K V 7 blocker, XE-991, significantly increases the spontaneous contractility of gastric fundal and corpal smooth muscle strips in diabetic and also in control rats, but diabetic group exhibits significant increase in contraction in response to XE-991 than the control one (Table: 1 
Conclusion
The study reported that, retigabine significantly decreases the basal and cholinergic stimulated contractility of diabetic fundus and corpus more than control group. XE-991 significantly increases the basal and cholinergic stimulated contractility of diabetic fundus and corpus when compared to control group. K V 7 channel modulators could affect the gastric fundal and corpal motility in type I diabetic rats, a possible new strategy that might be involved in management of diabetic gastro-enteropathy.
Recommendations:
Further research is recommended to study the protein expression of K V 7 channel in diabetic GI smooth muscle. And also to study the role of K V 7 channel in controlling GI motility in-vivo in type I and II diabetic animal models and also, in humans. 
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